-+ 0.00%
-+ 0.00%
-+ 0.00%
BioLineRx Agrees To Sell Its Rights To Certain Future Royalty Payments From APHEXDA To Soleus Capital Management And Its Affiliates For One-Time Payment Of $5.6M
Share
Listen to the news

- Transaction provides non-dilutive capital through sale of BioLineRx's portion of future APHEXDA royalties -

- Funds to support clinical development of GLIX1, including ongoing Phase 1/2a clinical trial, which is currently enrolling the fourth of five planned dosing cohorts -

- BioLineRx retains rights to future commercial milestone payments under its existing license agreement with Ayrmid -

TEL AVIV, Israel, Nov. 18, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it has entered into an agreement for the sale of its rights to certain future royalty payments from APHEXDA® (motixafortide) to Soleus Capital Management, L.P. and its affiliates ("Soleus") for a one-time payment of $5.6 million.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending